Tumorigenesis in Down's syndrome: Big lessons from a small chromosome

Nature Reviews Cancer

Volumn 12, Issue 10, 2012, Pages 721-732

  Nižetić, Dean ^a   Groet, Jürgen ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGIOGENIC ACTIVITY; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CHILDHOOD LEUKEMIA; DOWN SYNDROME; HUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

AGING; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; STEM CELLS;

EID: 84866735729     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3355     Document Type: Review

References (174)

1. Down, J. L. H. Observation on an ethnic classification of idiots. Lond. Hosp. Rep. 3, 259-262 (1866).
2. Boys, C. et al. Prenatal screening for Down's syndrome: editorial responsibilities. Lancet 372, 1789-1791 (2008).
3. de Graaf, G. et al. Changes in yearly birth prevalence rates of children with Down syndrome in the period 1986-2007 in The Netherlands. J. Intellect. Disabil. Res. 55, 462-473 (2011).
4. Savitz, D. A. How far can prenatal screening go in preventing birth defects? J. Pediatr. 152, 3-4 (2008).
5. Morad, M., Kandel, I., Merrick-Kenig, E. & Merrick, J. Persons with Down syndrome in residential care in Israel: trends for 1998-2006. Int. J. Adolesc. Med. Health 21, 131-134 (2009).
6. Hasle, H., Clemmensen, I. H. & Mikkelsen, M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355, 165-169 (2000).
7. Krivit, W. & Good, R. A. Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. AMA J. Dis. Child 94, 289-293 (1957).
8. Zipursky, A., Poon, A. & Doyle, J. Leukemia in Down syndrome: a review. Pediatr. Hematol. Oncol. 9, 139-149 (1992).
9. Yang, Q., Rasmussen, S. A. & Friedman, J. M. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 359, 1019-1025 (2002).
10. Al-Kasim, F., Doyle, J. J., Massey, G. V., Weinstein, H. J. & Zipursky, A. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J. Pediatr. Hematol. Oncol. 24, 9-13 (2002).
11. Malinge, S., Izraeli, S. & Crispino, J. D. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 11 3, 2619-2628 (2009).
12. McElwaine, S. et al. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br. J. Haematol. 125, 729-742 (2004).
13. Klusmann, J. H. et al. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev. 24, 1659-1672 (2010).
14. Wechsler, J. et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genet. 32, 148-152 (2002).
15. Groet, J. et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet 361, 1617-1620 (2003).
16. Bercovich, D. et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372, 1484-1492 (2008).
17. Kearney, L. et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 11 3, 646-648 (2009).
18. Hertzberg, L. et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 11 5, 1006-1017 (2010).
19. Russell, L. J. et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 11 4, 2688-2698 (2009).
20. Satge, D. et al. An ovarian dysgerminoma in Down syndrome. Hypothesis about the association. Int. J. Gynecol. Cancer 16, S375-S379 (2006).
21. Tanabe, M. et al. Intracranial germinoma with Down's syndrome: a case report and review of the literature. Surg. Neurol. 47, 28-31 (1997).
22. Goldacre, M. J., Wotton, C. J., Seagroatt, V. & Yeates, D. Cancers and immune related diseases associated with Down's syndrome: a record linkage study. Arch. Dis. Child 89, 1014-1017 (2004).
23. Hasle, H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2, 429-436 (2001).
24. Hermon, C., Alberman, E., Beral, V. & Swerdlow, A. J. Mortality and cancer incidence in persons with Down's syndrome, their parents and siblings. Ann. Hum. Genet. 65, 167-176 (2001).
25. Hill, D. A. et al. Mortality and cancer incidence among individuals with Down syndrome. Arch. Intern. Med. 163, 705-711 (2003).
26. Patja, K., Pukkala, E., Sund, R., Iivanainen, M. & Kaski, M. Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int. J. Cancer 11 8, 1769-1772 (2006).
27. Gilbert, D., Rapley, E. & Shipley, J. Testicular germ cell tumours: predisposition genes and the male germ cell niche. Nature Rev. Cancer 11, 278-288 (2011).
28. Miki, M., Ohtake, N., Hasumi, M., Ohi, M. & Moriyama, S. Seminoma associated with bilateral cryptorchidism in Down's syndrome: a case report. Int. J. Urol. 6, 377-380 (1999).
29. Cools, M. et al. Maturation delay of germ cells in fetuses with trisomy 21 results in increased risk for the development of testicular germ cell tumors. Hum. Pathol. 37, 101-111 (2006).
30. Boker, L. K. et al. Incidence of leukemia and other cancers in Down syndrome subjects in Israel. Int. J. Cancer 93, 741-744 (2001).
31. Nishi, M., Miyake, H., Takeda, T. & Hatae, Y. Congenital malformations and childhood cancer. Med. Pediatr. Oncol. 34, 250-254 (2000).
32. Scholl, T., Stein, Z. & Hansen, H. Leukemia and other cancers, anomalies and infections as causes of death in Down's syndrome in the United States during 1976. Dev. Med. Child Neurol. 24, 817-829 (1982).
33. Day, S. M., Strauss, D. J., Shavelle, R. M. & Reynolds, R. J. Mortality and causes of death in persons with Down syndrome in California. Dev. Med. Child Neurol. 47, 171-176 (2005).
34. Satge, D., Sasco, A. J. & Lacour, B. Are solid tumours different in children with Down's syndrome? Int. J. Cancer 106, 297-298 (2003).
35. Satge, D. et al. A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res. 58, 448-452 (1998).
36. Duesberg, P. & Rasnick, D. Aneuploidy, the somatic mutation that makes cancer a species of its own. Cell Motil. Cytoskeleton 47, 81-107 (2000).
37. Schvartzman, J. M., Sotillo, R. & Benezra, R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nature Rev. Cancer 10, 102-115 (2010).
38. Gordon, D. J., Resio, B. & Pellman, D. Causes and consequences of aneuploidy in cancer. Nature Rev. Genet. 13, 189-203 (2012).
39. Holland, A. J. & Cleveland, D. W. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nature Rev. Mol. Cell Biol. 10, 478-487 (2009).
40. Amiel, A., Goldzak, G., Gaber, E. & Fejgin, M. D. Molecular cytogenetic characteristics of Down syndrome newborns. J. Hum. Genet. 51, 541-547 (2006).
41. Hadi, E. et al. Telomere aggregates in trisomy 21 amniocytes. Cancer Genet. Cytogenet. 195, 23-26 (2009).
42. Jenkins, E. C. et al. Increased low-level chromosome 21 mosaicism in older individuals with Down syndrome. Am. J. Med. Genet. 68, 147-151 (1997).
43. Percy, M. E. et al. Age-associated chromosome 21 loss in Down syndrome: possible relevance to mosaicism and Alzheimer disease. Am. J. Med. Genet. 45, 584-588 (1993).
44. Lightfoot, D. A. & Hoog, C. Low level chromosome instability in embryonic cells of primary aneuploid mice. Cytogenet. Genome Res. 107, 95-98 (2004).
45. Reish, O., Regev, M., Kanesky, A., Girafi, S. & Mashevich, M. Sporadic aneuploidy in PHA-stimulated lymphocytes of trisomies 21, 18, and 13. Cytogenet. Genome Res. 133, 184-189 (2011).
46. Ganmore, I., Smooha, G. & Izraeli, S. Constitutional aneuploidy and cancer predisposition. Hum. Mol. Genet. 18, R84-R93 (2009).
47. Schoemaker, M. J., Swerdlow, A. J., Higgins, C. D., Wright, A. F. & Jacobs, P. A. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. Lancet Oncol. 9, 239-246 (2008).
48. Swerdlow, A. J. et al. Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: a cohort study. Ann. Hum. Genet. 65, 177-188 (2001).
49. Forestier, E. et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood 111, 1575-1583 (2008).
50. Blink, M. et al. High frequency of copy number alterations in myeloid leukaemia of Down syndrome. Br. J. Haematol. 7 Jul 2012 (doi:10.1111/j.1365- 2141.2012.09224.x).
51. Clark, J. P. & Cooper, C. S. ETS gene fusions in prostate cancer. Nature Rev. Urol. 6, 429-439 (2009).
52. Busciglio, J. & Yankner, B. A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378, 776-779 (1995).
53. Coskun, P. E. et al. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J. Alzheimers Dis. 20, S293-S310 (2010).
54. Ishihara, K. et al. Increased lipid peroxidation in Down's syndrome mouse models. J. Neurochem. 110, 1965-1976 (2009).
55. Komatsu, T. et al. Reactive oxygen species generation in gingival fibroblasts of Down syndrome patients detected by electron spin resonance spectroscopy. Redox Rep. 11, 71-77 (2006).
56. Morawiec, Z. et al. DNA damage and repair in children with Down's syndrome. Mutat. Res. 637, 118-123 (2008).
57. Zana, M. et al. Age-dependent oxidative stress-induced DNA damage in Down's lymphocytes. Biochem. Biophys. Res. Commun. 345, 726-733 (2006).
58. Del Bo, R. et al. Down's syndrome fibroblasts anticipate the accumulation of specific ageing-related mtDNA mutations. Ann. Neurol. 49, 137-138 (2001).
59. de Haan, J. B. et al. Elevation in the ratio of Cu/Zn-superoxide dismutase to glutathione peroxidase activity induces features of cellular senescence and this effect is mediated by hydrogen peroxide. Hum. Mol. Genet. 5, 283-292 (1996).
60. Lee, M., Hyun, D., Jenner, P. & Halliwell, B. Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis. J. Neurochem. 76, 957-965 (2001).
61. Roat, E. et al. Mitochondrial alterations and tendency to apoptosis in peripheral blood cells from children with Down syndrome. FEBS Lett. 581, 521-525 (2007).
62. Valenti, D., Manente, G. A., Moro, L, Marra, E. & Vacca, R. A. Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway. Biochem. J. 435, 679-688 (2011).
63. Athanasiou, K., Sideris, E. G. & Bartsocas, C. Decreased repair of x-ray induced DNA single-strand breaks in lymphocytes in Down's syndrome. Pediatr. Res. 14, 336-338 (1980).
64. Druzhyna, N., Nair, R. G., LeDoux, S. P. & Wilson, G. L. Defective repair of oxidative damage in mitochondrial DNA in Down's syndrome. Mutat. Res. 409, 81-89 (1998).
65. Raji, N. S. & Rao, K. S. Trisomy 21 and accelerated aging: DNA-repair parameters in peripheral lymphocytes of Down's syndrome patients. Mech. Ageing Dev. 100, 85-101 (1998).
66. Cabelof, D. C. et al. Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome. Blood 114, 2753-2763 (2009).
67. Ram, G. & Chinen, J. Infections and immunodeficiency in Down syndrome. Clin. Exp. Immunol. 164, 9-16 (2011).
68. Guazzarotti, L. et al. T lymphocyte maturation is impaired in healthy young individuals carrying trisomy 21 (Down syndrome). Am. J. Intellect Dev. Disabil. 114, 100-109 (2009).
69. Lima, F A. et al. Decreased AIRE expression and global thymic hypofunction in Down syndrome. J. Immunol. 187, 3422-3430 (2011).
70. + cells: evidence for an inefficient release of mature T cells by the DS thymus. Clin. Immunol. Immunopathol. 62, 245-251 (1992).
71. Hayday, A. C. yôT cells and the lymphoid stress-surveillance response. Immunity 31, 184-196 (2009).
72. Zwaan, C. M. et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 99, 245-251 (2002).
73. Peterson, A. J. et al. Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans. Gastroenterology 139, 2005-2017 (2010).
74. Luzza, F. et al. High seroprevalence of Helicobacter pylori infection in non-institutionalised children with mental retardation. Clin. Microbiol. Infect. 10, 670-673 (2004).
75. Wallace, R. A. Clinical audit of gastrointestinal conditions occurring among adults with Down syndrome attending a specialist clinic. J. Intellect. Dev. Disabil. 32, 45-50 (2007).
76. Faruqi, S. A., Noumoff, M. J., Deger, R. B., Jalal, S. M. & Antoniades, K. Trisomy 21 as the only recurrent chromosomal anomaly in a clinically aggressive ovarian carcinoma. Cancer Genet. Cytogenet. 138, 165-168 (2002).
77. Berger, R. Acute lymphoblastic leukemia and chromosome 21. Cancer Genet. Cytogenet. 94, 8-12 (1997).
78. Bacher, U. et al. Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2, 235 patients. Ann. Hematol. 84, 785-791 (2005).
79. Prandini, P. et al. Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am. J. Hum. Genet. 81, 252-263 (2007).
80. Rainis, L. et al. The proto-oncogene ERG in megakaryoblastic leukemias. Cancer Res. 65, 7596-7602 (2005).
81. Klusmann, J. H. et al. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev. 24, 478-490 (2010).
82. Salek-Ardakani, S. et al. ERG is a megakaryocytic oncogene. Cancer Res. 69, 4665-4673 (2009).
83. Stankiewicz, M. J. & Crispino, J. D. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood 11 3, 3337-3347 (2009).
84. Alford, K. A. et al. Perturbed hematopoiesis in the Tc 1 mouse model of Down syndrome. Blood 11 5, 2928-2937 (2010).
85. Ng, A. P. et al. Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome. Blood 11 5, 3966-3969 (2009).
86. Malinge, S. et al. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J. Clin. Invest. 122, 948-962 (2012).
87. Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A. & Deutsch, S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nature Rev. Genet. 5, 725-738 (2004).
88. Canzonetta, C. et al. Amplified segment in the 'Down Syndrome critical region' on HSA21 shared between Down syndrome and euploid AML-M0 excludes RUNX1, ERG and ETS2. Br. J. Haematol. 157, 197-200 (2012).
89. Silva, F. P. et al. Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. Haematologica 94, 1546-1554 (2009).
90. Delom, F. et al. Transchromosomic cell model of Down syndrome shows aberrant migration, adhesion and proteome response to extracellular matrix. Proteome Sci. 7, 31 (2009).
91. Kimura, M. et al. Proliferation dynamics in cultured skin fibroblasts from Down syndrome subjects. Free Radic. Biol. Med. 39, 374-380 (2005).
92. Sussan, T. E., Yang, A., Li, F., Ostrowski, M. C. & Reeves, R. H. Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature 451, 73-75 (2008).
93. Xu, D., Dwyer, J., Li, H., Duan, W. & Liu, J. P. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J. Biol. Chem. 283, 23567-23580 (2008).
94. Wolvetang, E. J. et al. ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway. Hum. Mol. Genet. 12, 247-255 (2003).
95. 2-induced apoptosis: implications for Down's syndrome. Biochem. Biophys. Res. Commun. 287, 1003-1008 (2001).
96. Laguna, A. et al. The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. Dev. Cell 15, 841-853 (2008).
97. Park, J. et al. Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. J. Biol. Chem. 285, 31895-31906 (2010).
98. Litovchick, L., Florens, L. A., Swanson, S. K., Washburn, M. P. & DeCaprio, J. A. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev. 25, 801-813 (2011).
99. Hammerle, B. et al. Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. Development 138, 2543-2554 (2011).
100. Canzonetta, C. et al. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am. J. Hum. Genet. 83, 388-400 (2008).
101. Westbrook, T. F. et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 121, 837-848 (2005).
102. Kreisler, A. et al. Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer. Oncogene 29, 5828-5838 (2010).
103. Guardavaccaro, D. et al. Control of chromosome stability by the β-TrCP-REST-Mad2 axis. Nature 452, 365-369 (2008).
104. Lepagnol-Bestel, A. M. et al. DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. Hum. Mol. Genet. 18, 1405-1414 (2009).
105. Lu, M. et al. REST regulates DYRK1A transcription in a negative feedback loop. J. Biol. Chem. 286, 10755-10763 (2011).
106. Zhang, Y., Liao, J. M., Zeng, S. X. & Lu, H. p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep. 12, 811-817 (2011).
107. Birger, Y. & Izraeli, S. DYRK1A in Down syndrome: an oncogene or tumor suppressor? J. Clin. Invest. 122, 807-810 (2012).
108. Zorick, T. S. et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur. J. Hum. Genet. 9, 811-814 (2001).
109. Herbst, R. S. et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 20, 3792-3803 (2002).
110. Ryeom, S., Greenwald, R. J., Sharpe, A. H. & McKeon, F. The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin. Nature Immunol. 4, 874-881 (2003).
111. Baek, K. H. et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459, 1126-1130 (2009).
112. Yang, A. & Reeves, R. H. Increased survival following tumorigenesis in Ts65Dn mice that model Down syndrome. Cancer Res. 71, 3573-3581 (2011).
113. Arron, J. R. et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595-600 (2006).
114. O'Doherty, A. et al. An aneuploid mouse strain carrying human chromosome 21 with down syndrome phenotypes. Science 309, 2033-2037 (2005).
115. Reynolds, L. E. et al. Tumour angiogenesis is reduced in the Tc 1 mouse model of Down's syndrome. Nature 465, 813-817 (2010).
116. Chen, C. P. et al. Fetal cervico-mediastinal cystic hygroma associated with maternal serum screening positive for Down syndrome. Prenat. Diagn. 22, 166 (2002).
117. Fountzilas, G. et al. Extragonadal choriocarcinoma in a patient with Down syndrome. Am. J. Clin. Oncol. 17, 452-455 (1994).
118. Krapp, M. et al. Tuberous sclerosis with intracardiac rhabdomyoma in a fetus with trisomy 21: case report and review of literature. Prenat. Diagn. 19, 610-613 (1999).
119. Tan, H. W. et al. Pineal yolk sac tumour with a solid pattern: a case report in a Chinese adult man with Down's syndrome. J. Clin. Pathol. 57, 882-884 (2004).
120. Taub, J. W. et al. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood 104, 1588-1589 (2004).
121. Wiemels, J. L. et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354, 1499-1503 (1999).
122. Spencer, K. What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester? Prenat. Diagn. 21, 788-789 (2001).
123. Kai, Y. et al. Enhanced apoptosis during early neuronal differentiation in mouse ES cells with autosomal imbalance. Cell Res. 19, 247-258 (2009).
124. Mensah, A. et al. An additional human chromosome 21 causes suppression of neural fate of pluripotent mouse embryonic stem cells in a teratoma model. BMC Dev. Biol. 7, 131 (2007).
125. Bahn, S. et al. Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with Down's syndrome: a gene expression study. Lancet 359, 310-315 (2002).
126. Roper, R. J. et al. Defective cerebellar response to mitogenic Hedgehog signaling in Down's syndrome mice. Proc. Natl Acad. Sci. USA 103, 1452-1456 (2006).
127. Subkhankulova, T., Zhang, X., Leung, C. & Marino, S. Bmi1 directly represses p21Waf1/Cip1 in Shh-induced proliferation of cerebellar granule cell progenitors. Mol. Cell. Neurosci. 45, 151-162 (2010).
128. De Vita, S. et al. Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome. Oncogene 29, 6102-6114 (2010).
129. Chou, S. T. et al. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood 11 2, 4503-4506 (2008).
130. Tunstall-Pedoe, O. et al. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood 11 2, 4507-4511 (2008).
131. Li, Z. et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nature Genet. 37, 613-619 (2005).
132. De Vita, S. et al. Megakaryocyte hyperproliferation without GATA1 mutation in foetal liver of a case of Down syndrome with hydrops foetalis. Br. J. Haematol. 143, 300-303 (2008).
133. Rougemont, A. L. et al. Myeloid proliferation without GATA1 mutations in a fetus with Down syndrome presenting in utero as a pericardial effusion. Pediatr. Dev. Pathol. 13, 423-426 (2010).
134. Henry, E., Walker, D., Wiedmeier, S. E. & Christensen, R. D. Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system. Am. J. Med. Genet. A 143, 42-50 (2007).
135. De Vita, S. et al. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome. Br. J. Haematol. 137, 337-341 (2007).
136. Groet, J. et al. Independent clones at separable stages of differentiation, bearing different GATA1 mutations, in the same TMD patient with Down syndrome. Blood 106, 1887-1888 (2005).
137. Walters, D. K. et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10, 65-75 (2006).
138. Vaziri, H. et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am. J. Hum. Genet. 52, 661-667 (1993).
139. Holmes, D. K. et al. Hematopoietic progenitor cell deficiency in fetuses and children affected by Down's syndrome. Exp. Hematol. 34, 1611-1615 (2006).
140. Lorenzo, L. P. et al. Defective hematopoietic stem cell and lymphoid progenitor development in the Ts65Dn mouse model of Down syndrome: potential role of oxidative stress. Antioxid. Redox Signal. 15, 2083-2094 (2011).
141. Henry, C. J., Marusyk, A. & DeGregori, J. Aging-associated changes in hematopoiesis and leukemogenesis: what's the connection? Aging 3, 643-656 (2011).
142. Micali, N. et al. Down syndrome fibroblasts and mouse Prep1-overexpressing cells display increased sensitivity to genotoxic stress. Nucleic Acids Res. 38, 3595-3604 (2010).
143. Thomas, P., Harvey, S., Gruner, T. & Fenech, M. The buccal cytome and micronucleus frequency is substantially altered in Down's syndrome and normal ageing compared to young healthy controls. Mutat. Res. 638, 37-47 (2008).
144. Muntean, A. G., Ge, Y., Taub, J. W. & Crispino, J. D. Transcription factor GATA-1 and Down syndrome leukemogenesis. Leuk. Lymphoma 47, 986-997 (2006).
145. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870 (2005).
146. d'Adda di Fagagna, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198 (2003).
147. Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913 (2005).
148. Takai, H., Smogorzewska, A. & de Lange, T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 13, 1549-1556 (2003).
149. Bartkova, J. et al. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26, 7414-7422 (2007).
150. Cuadrado, E. & Barrena, M. J. Immune dysfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system? Clin. Immunol. Immunopathol. 78, 209-214 (1996).
151. da Silva, V. Z. et al. Bone mineral density and respiratory muscle strength in male individuals with mental retardation (with and without Down Syndrome). Res. Dev. Disabil. 31, 1585-1589 (2010).
152. Roizen, N. J. & Patterson, D. Down's syndrome. Lancet 361, 1281-1289 (2003).
153. Greaves, M. Leukemogenesis and ageing: 'fit for transformation'? Aging 3, 79-80 (2011).
154. Gibbons, D. L. et al. An E mu-BCL-2 transgene facilitates leukaemogenesis by ionizing radiation. Oncogene 18, 3870-3877 (1999).
155. Preston, D. L. et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat. Res. 137, S68-S97 (1994).
156. Tokunaga, M. et al. Incidence of female breast cancer among atomic bomb survivors, 1950-1985. Radiat. Res. 138, 209-223 (1994).
157. Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361 (2011).
158. McLean, S., McHale, C. & Enright, H. Hematological abnormalities in adult patients with Down's syndrome. Ir. J. Med. Sci. 178, 35-38 (2009).
159. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007).
160. Groet, J. et al. Narrowing of the region of allelic loss in 21q11-21 in squamous non-small cell lung carcinoma and cloning of a novel ubiquitin-specific protease gene from the deleted segment. Genes Chromosomes Cancer 27, 153-161 (2000).
161. Yamada, H. et al. Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes Chromosomes Cancer 47, 810-818 (2008).
162. Johnson, S. M. et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635-647 (2005).
163. Shaham, L., Binder, V., Gefen, N., Borkhardt, A. & Izraeli, S. MiR-125 in normal and malignant hematopoiesis. Leukemia 24 Apr 2012 (doi:10.1038/leu.2012.90).
164. Yamamoto, N. et al. Analysis of the ANA gene as a candidate for the chromosome 21q oral cancer susceptibility locus. Br. J. Cancer 84, 754-759 (2001).
165. Gironella, M. et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc. Natl Acad. Sci. USA 104, 16170-16175 (2007).
166. Chessells, J. M. et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch. Dis. Child. 85, 321-325 (2001).
167. Mori, H. et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Natl Acad. Sci. USA 99, 8242-8247 (2002).
168. Rand, V. et al. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood 11 7, 6848-6855 (2011).
169. Gustafson, T. L. et al. Ha-Ras transformation of MCF10A cells leads to repression of Singleminded-2s through NOTCH and C/EBPβ. Oncogene 28, 1561-1568 (2009).
170. Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Med. 17, 1086-1093 (2011).
171. Ginsberg, J. P. et al. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J. Clin. Oncol. 17, 1809-1814 (1999).
172. Ohtani, N. et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409, 1067-1070 (2001).
173. Lefebvre, O. et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 274, 259-262 (1996).
174. British Broadcasting Corporation. Many keeping babies with Down's. BBC News [online], http://news. bbc.co.uk/1/hi/health/7741411.stm (2008).